Edessa vs Eden
Two flat-rate sellers nineteen dollars apart across the same footprint.
Edessa
Editorial
$179/mo
Compounded semaglutide in both an injection and a tablet, plus compounded tirzepatide, each with a three-term plan table. The injection is $179 for one month; the homepage's $135 is the six-month prepay rate. Rates are stated to hold flat as the dose rises.
Pick it for: Buyers who want the lower held rate and a third priced line
Eden
Editorial
$198/mo
Compounded semaglutide and compounded tirzepatide by injection, each priced as medication alone at $99 and $199 a month. The Eden Membership is a further $99 and the GLP-1 page states it is required, so one month is $198 or $298. The rate is stated to hold at every dose across 50 states.
Pick it for: Buyers who want the simpler two-line catalog
Our verdict
Edessa opens at $179 and Eden at $198, and both state the rate holds at every dose. Six months is $1,074 against $1,188, a difference of $114 over a half-year. Edessa prices a third line where Eden prices two, so the cheaper seller is also the one with more to choose from. Eden's footprint is the rounder fifty states against Edessa's fifty-one, which includes the District of Columbia. On terms the two are unusually close, and the money is the argument.
What actually separates them
Edessa and Eden state different things about published price and where you can use it. Everything else they publish, they publish the same way.
Eden costs $19 more than Edessa — 11% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $2,148 at Edessa against $2,376 at Eden — a difference of $228.
| Edessa | Eden | |
|---|---|---|
| Published price | $179/mo | $198/mo |
| Where you can use it | All 50 states and the District of Columbia | 50 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.